The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
-
Clinical Trial Site, La Jolla, California, United States, 92037
Clinical Trial Site, Los Angeles, California, United States, 90095
Clinical Trial Site, Jacksonville, Florida, United States, 32224
Clinical Trial Site, Iowa City, Iowa, United States, 52242
Clinical Trial Site, Kansas City, Kansas, United States, 66160
Clinical Trial Site, Baltimore, Maryland, United States, 21224
Clinical Trial Site, Boston, Massachusetts, United States, 02127
Clinical Trial Site, New York, New York, United States, 10034
Clinical Trial Site, Durham, North Carolina, United States, 27710
Clinical Trial Site, Columbus, Ohio, United States, 43210
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Alnylam Pharmaceuticals,
Medical Director, STUDY_DIRECTOR, Alnylam Pharmaceuticals
2030-09-01